These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 11257404)

  • 1. Genetic adjuvants for DNA vaccines.
    Scheerlinck JY
    Vaccine; 2001 Mar; 19(17-19):2647-56. PubMed ID: 11257404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant formulations and delivery systems for DNA vaccines.
    Sasaki S; Takeshita F; Xin KQ; Ishii N; Okuda K
    Methods; 2003 Nov; 31(3):243-54. PubMed ID: 14511957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of DNA vaccines using molecular adjuvant plasmids.
    Sin JI; Kim J; Chattergoon M; Ayyavoo V; McCallus D; Ugen KE; Boyer JD; Weiner DB
    Dev Biol (Basel); 2000; 104():187-98. PubMed ID: 11713819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of multicomponent DNA vaccination strategies against HIV.
    Kim JJ; Weiner DB
    Curr Opin Mol Ther; 1999 Feb; 1(1):43-9. PubMed ID: 11249683
    [No Abstract]   [Full Text] [Related]  

  • 5. DNA vaccines--challenges in delivery.
    Pachuk CJ; McCallus DE; Weiner DB; Satishchandran C
    Curr Opin Mol Ther; 2000 Apr; 2(2):188-98. PubMed ID: 11249641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutting edge: a potent adjuvant effect of ligand to receptor activator of NF-kappa B gene for inducing antigen-specific CD8+ T cell response by DNA and viral vector vaccination.
    Miyahira Y; Akiba H; Katae M; Kubota K; Kobayashi S; Takeuchi T; García-Sastre A; Fukuchi Y; Okumura K; Yagita H; Aoki T
    J Immunol; 2003 Dec; 171(12):6344-8. PubMed ID: 14662831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD63-Mediated Antigen Delivery into Extracellular Vesicles via DNA Vaccination Results in Robust CD8
    Kanuma T; Yamamoto T; Kobiyama K; Moriishi E; Masuta Y; Kusakabe T; Ozasa K; Kuroda E; Jounai N; Ishii KJ
    J Immunol; 2017 Jun; 198(12):4707-4715. PubMed ID: 28507029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative efficacy of CTLA-4 and L-selectin targeted DNA vaccines in mice and sheep.
    Drew DR; Boyle JS; Lew AM; Lightowlers MW; Chaplin PJ; Strugnell RA
    Vaccine; 2001 Aug; 19(31):4417-28. PubMed ID: 11483267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of human immunodeficiency virus type 1-DNA vaccine potency through incorporation of T-helper 1 molecular adjuvants.
    Calarota SA; Weiner DB
    Immunol Rev; 2004 Jun; 199():84-99. PubMed ID: 15233728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvants.
    Kim JJ; Yang JS; Manson KH; Weiner DB
    Vaccine; 2001 Mar; 19(17-19):2496-505. PubMed ID: 11257383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNA vaccine strategies: candidates for immune modulation and immunization regimens.
    Doria-Rose NA; Haigwood NL
    Methods; 2003 Nov; 31(3):207-16. PubMed ID: 14511953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in adjuvants for vaccines against infectious diseases.
    O'Hagan DT; MacKichan ML; Singh M
    Biomol Eng; 2001 Oct; 18(3):69-85. PubMed ID: 11566599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Augmentation and suppression of immune responses to an HIV-1 DNA vaccine by plasmid cytokine/Ig administration.
    Barouch DH; Santra S; Steenbeke TD; Zheng XX; Perry HC; Davies ME; Freed DC; Craiu A; Strom TB; Shiver JW; Letvin NL
    J Immunol; 1998 Aug; 161(4):1875-82. PubMed ID: 9712056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Strategies for improved formulation and delivery of DNA vaccines to veterinary target species.
    van Drunen Littel-van den Hurk S; Babiuk SL; Babiuk LA
    Immunol Rev; 2004 Jun; 199():113-25. PubMed ID: 15233730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of immune response to a DNA vaccine against Mycobacterium tuberculosis Ag85B by incorporation of an autophagy inducing system.
    Meerak J; Wanichwecharungruang SP; Palaga T
    Vaccine; 2013 Jan; 31(5):784-90. PubMed ID: 23228812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine.
    Velders MP; Weijzen S; Eiben GL; Elmishad AG; Kloetzel PM; Higgins T; Ciccarelli RB; Evans M; Man S; Smith L; Kast WM
    J Immunol; 2001 May; 166(9):5366-73. PubMed ID: 11313372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nucleic acid vaccines: tasks and tactics.
    McKenzie BS; Corbett AJ; Brady JL; Dyer CM; Strugnell RA; Kent SJ; Kramer DR; Boyle JS; Lew AM
    Immunol Res; 2001; 24(3):225-44. PubMed ID: 11817323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multivalent minigene vaccines against infectious disease.
    An LL; Whitton JL
    Curr Opin Mol Ther; 1999 Feb; 1(1):16-21. PubMed ID: 11249678
    [No Abstract]   [Full Text] [Related]  

  • 19. Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies.
    Kim TW; Hung CF; Boyd D; Juang J; He L; Kim JW; Hardwick JM; Wu TC
    J Immunol; 2003 Sep; 171(6):2970-6. PubMed ID: 12960321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic vaccines.
    Haynes JR
    Infect Dis Clin North Am; 1999 Mar; 13(1):11-26, v. PubMed ID: 10198789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.